Evidence-based care pathways create clearer routes to adoption

Tern plc

Evidence-based care pathways help healthcare systems make more consistent decisions across diagnosis, treatment and long-term disease management. They give clinicians a clearer framework for deciding what should happen, when it should happen and which factors should influence the next step.

Their value lies in reducing avoidable variation. Without a defined pathway, patients with similar conditions may receive different tests, referrals or treatments depending on where they are seen. A stronger pathway can support earlier action, clearer responsibilities and more efficient use of healthcare resources.

Diagnosis is often the first pressure point. Many conditions begin with symptoms that are difficult to distinguish from other illnesses. Delays can also arise from limited access to specialists, inconsistent referral processes and differences in local diagnostic capacity.

A well-designed pathway can reduce these risks by setting out when further investigation is needed and when specialist input should be sought. It can also help clinicians use patient-reported symptoms more effectively, especially where the impact on daily life is not fully captured by routine clinical measures.

Earlier diagnosis can improve the timing of treatment. In some conditions, this may reduce progression, limit complications and improve the patient’s long-term outlook. It can also reduce the cost and complexity created by repeated appointments, delayed referrals and unnecessary testing.

Treatment decisions are becoming more complex as the number of therapies increases. Clinicians must consider efficacy, safety, disease severity, previous treatment, comorbidities and patient preferences. In some cases, biomarker data and other diagnostic information also shape the decision.

Care pathways bring these factors together in a more structured way. They can define when treatment should begin, how it should be monitored and when it should be changed. This supports consistency while still allowing clinicians to adapt decisions to the individual patient.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern portfolio company Talking Medicines launches ‘Intent to Prescribe’ DrugVoice application

Talking Medicines has launched a new DrugVoice application combining its Message Resonance Score™ with near-real-time point-of-care data to help pharmaceutical companies assess links between HCP message alignment and prescribing intent.

Device Authority targets secure digital infrastructure for smart ports

Device Authority's Smart, Green Port Blueprint shows how secure device management can support the wider rollout of connected infrastructure across modern ports.

Talking Medicines highlights strategic signals emerging across the GLP-1 consumer market

GLP-1 consumers are increasingly weighing access, affordability, quality, clinical oversight and treatment support, creating new strategic considerations across the wider life sciences market.

Tern Plc launches £509,368 underwritten Open Offer

Tern Plc has announced an underwritten Open Offer to raise approximately £509,368 through the issue of 56.6 million shares at 0.90p each. Qualifying shareholders may subscribe for one new share for every 16 shares held, with the offer closing on 22 September 2026.

Talking Medicines targets a growing data need around GLP-1 treatment journeys

Talking Medicines is using GLP-1 discontinuation conversations to show how DrugVoice can help pharmaceutical companies track changing patient needs across the treatment journey.

Device Authority adopts usage-based pricing to support KeyScaler expansion

Device Authority has moved KeyScaler to usage-based pricing, aiming to reduce licensing friction and support broader adoption of its machine identity security platform.

Search